AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.
This video was recorded at the AHA in Philadelphia, USA, on November 17, 2019.
Scott David Solomon is Director Noninvasive Cardiology, Cardiovascular Medicine, Brigham and Women's Hospital and Professor at Harvard Medical School, Boston, MA, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- AHA 2019A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
Prof. Freek Verheugt, MD
Prof. Stephen Nicholls
Prof. Donald Lloyd-Jones